Summary & Overview
HCPCS Level II Q5100: Ustekinumab-kfce (Yesintek) Injection, 1 mg
HCPCS Level II code Q5100 denotes the biosimilar product ustekinumab-kfce (Yesintek), billed per 1 mg unit for parenteral administration. As a biosimilar to ustekinumab, this code facilitates billing for the medication itself rather than the administration procedure, which is typically reported separately. Nationally, biologic and biosimilar billing codes like Q5100 matter because they affect formularies, payer coverage policies, and cost management strategies for chronic immune-mediated conditions treated with ustekinumab-class agents.
Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise overview of the code’s clinical role, typical sites of service, and the payer landscape relevant to coverage and billing. The publication summarizes benchmarks where available, notes recent policy updates affecting biosimilar adoption, and provides clinical context about the medication class and billing implications. Where specific payer or clinical detail is not present in the source input, the report notes that data is not available in the input.
Billing Code Overview
HCPCS Level II code Q5100 represents an injection of ustekinumab-kfce (Yesintek), biosimilar, 1 mg. This code denotes a biologic biosimilar formulation of ustekinumab used for parenteral administration.
Service Type: Injectable biologic medication administration / drug supply
Typical Site of Service: Outpatient infusion or clinic setting, physician office, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with moderate-to-severe plaque psoriasis presents to an outpatient infusion clinic for administration of a maintenance dose of the ustekinumab biosimilar Q5100 (ustekinumab-kfce, Yesintek) formulated as an injectable. The patient has previously completed induction dosing and returns for scheduled maintenance injections every 12 weeks. The clinical workflow includes verification of patient identity and insurance, review of current medications and infection screening (including tuberculosis screening per institution protocol), assessment of baseline vitals and weight, documentation of any adverse events or infections since last dose, and preparation of the single-dose prefilled syringe or vial. A licensed clinician (physician, nurse practitioner, physician assistant, or registered nurse) performs the subcutaneous injection in an exam room or dedicated biologic therapy clinic. Post-injection observation for allergic reaction is performed per clinic policy. Billing for the drug is reported with the HCPCS Level II code Q5100, and any applicable modifiers are appended according to payer and clinical circumstances. Documentation includes indication, dose administered in milligrams, lot number, expiration date, injection site, and patient response.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard) |